Melanoma: epidemiology, pathogenesis, and new modes of treatment - PubMed (original) (raw)
Affiliations
- PMID: 8903599
Review
Melanoma: epidemiology, pathogenesis, and new modes of treatment
L Dreiling et al. Adv Intern Med. 1996.
Abstract
The treatment of patients with advanced stage (stage III and IV) melanoma remains discouraging. Except for the study using tamoxifen, combination chemotherapy (cisplatin, DTIC, BCNU), plus biological therapy (IFN-alpha and/or IL-2), which achieved a 57% response rate, virtually any combination of agents or modalities yielded response rates of only 20% to 30%, and none are effective in central nervous system metastases. Durable clinical cures in patients with advanced-stage disease are extremely rare and can probably be attributed more to host defense mechanisms than iatrogenic intervention. The future in treatment then can only look promising to immunologists, molecular biologists, and clinicians striving to elucidate the biological mechanisms isolated patients have for destroying melanoma cells and incorporating those mechanisms into therapeutics for the remainder of melanoma victims.
Similar articles
- Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L, Zeuli M, Sega FM, Cognetti F. Serrone L, et al. J Exp Clin Cancer Res. 2000 Mar;19(1):21-34. J Exp Clin Cancer Res. 2000. PMID: 10840932 - Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W. Hauschild A, et al. Br J Cancer. 2001 Apr 20;84(8):1036-42. doi: 10.1054/bjoc.2001.1731. Br J Cancer. 2001. PMID: 11308250 Free PMC article. Clinical Trial. - Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
Keilholz U, Stoter G, Punt CJ, Scheibenbogen C, Lejeune F, Eggermont AM. Keilholz U, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S22-8. Cancer J Sci Am. 1997. PMID: 9457389 Review. - A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Middleton MR, Lorigan P, Owen J, Ashcroft L, Lee SM, Harper P, Thatcher N. Middleton MR, et al. Br J Cancer. 2000 Mar;82(6):1158-62. doi: 10.1054/bjoc.1999.1056. Br J Cancer. 2000. PMID: 10735499 Free PMC article. Clinical Trial. - Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review).
Toma S, Ugolini D, Palumbo R. Toma S, et al. Int J Oncol. 1999 Aug;15(2):321-37. Int J Oncol. 1999. PMID: 10402244 Review.
Cited by
- Immune evasion by murine melanoma mediated through CC chemokine receptor-10.
Murakami T, Cardones AR, Finkelstein SE, Restifo NP, Klaunberg BA, Nestle FO, Castillo SS, Dennis PA, Hwang ST. Murakami T, et al. J Exp Med. 2003 Nov 3;198(9):1337-47. doi: 10.1084/jem.20030593. Epub 2003 Oct 27. J Exp Med. 2003. PMID: 14581607 Free PMC article. - Selective Killing of Melanoma Cells With Non-Thermal Atmospheric Pressure Plasma and p-FAK Antibody Conjugated Gold Nanoparticles.
Choi BBR, Choi JH, Hong JW, Song KW, Lee HJ, Kim UK, Kim GC. Choi BBR, et al. Int J Med Sci. 2017 Sep 4;14(11):1101-1109. doi: 10.7150/ijms.20104. eCollection 2017. Int J Med Sci. 2017. PMID: 29104464 Free PMC article. - A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma.
Strauss SJ, Marples M, Napier MP, Meyer T, Boxall J, Rustin GJ. Strauss SJ, et al. Br J Cancer. 2003 Nov 17;89(10):1901-5. doi: 10.1038/sj.bjc.6601414. Br J Cancer. 2003. PMID: 14612900 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Medical